Pexeva Side Effects

Generic Name: paroxetine

Note: This page contains side effects data for the generic drug paroxetine. It is possible that some of the dosage forms included below may not apply to the brand name Pexeva.

It is possible that some side effects of Pexeva may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

For the Consumer

Applies to paroxetine: oral capsule, oral suspension, oral tablet, oral tablet extended release

As well as its needed effects, paroxetine (the active ingredient contained in Pexeva) may cause unwanted side effects that require medical attention.

If any of the following side effects occur while taking paroxetine, check with your doctor immediately:

Less common
  • Agitation
  • chest congestion
  • chest pain
  • chills
  • cold sweats
  • confusion
  • difficulty with breathing
  • dizziness, faintness, or lightheadedness when getting up from a lying or sitting position
  • fast, pounding, or irregular heartbeat or pulse
  • muscle pain or weakness
  • skin rash
Rare
  • Absence of or decrease in body movements
  • bigger, dilated, or enlarged pupils (black part of the eye)
  • convulsions (seizures)
  • difficulty with speaking
  • dry mouth
  • fever
  • inability to move the eyes
  • incomplete, sudden, or unusual body or facial movements
  • increased sensitivity of the eyes to light
  • poor coordination
  • red or purple patches on the skin
  • restlessness
  • shivering
  • sweating
  • talking, feeling, and acting with excitement and activity you cannot control
  • trembling or shaking, or twitching
Incidence not known
  • Back, leg, or stomach pains
  • blindness
  • blistering, peeling, or loosening of the skin
  • blue-yellow color blindness
  • blurred vision
  • constipation
  • cough or hoarseness
  • dark urine
  • decreased frequency or amount of urine
  • decreased vision
  • difficulty with swallowing
  • electric shock sensations
  • eye pain
  • fainting
  • general body swelling
  • headache
  • high fever
  • hives
  • inability to move the arms and legs
  • inability to sit still
  • increased thirst
  • incremental or ratchet-like movement of the muscle
  • itching skin
  • joint pain
  • light-colored stools
  • lockjaw
  • loss of appetite
  • loss of bladder control
  • low blood pressure
  • lower back or side pain
  • muscle spasm, especially of the neck and back
  • muscle tension or tightness
  • painful or difficult urination
  • painful or prolonged erection of the penis
  • pale skin
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • raised red swellings on the skin, the buttocks, legs, or ankles
  • red, irritated eyes
  • sensitivity to the sun
  • skin redness or soreness
  • slow heart rate
  • sores, ulcers, or white spots on the lips or in the mouth
  • spasms of the throat
  • stiff muscles
  • stomach pain
  • sudden numbness and weakness in the arms and legs
  • swelling of the breasts
  • swelling of the face, fingers, or lower legs
  • swollen or painful glands
  • tightness in the chest
  • unexpected or excess milk flow from the breasts
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • vomiting
  • weight gain
  • yellowing of the eyes or skin

Some paroxetine side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:

More common
  • Acid or sour stomach
  • belching
  • decreased appetite
  • decreased sexual ability or desire
  • heartburn
  • pain or tenderness around the eyes and cheekbones
  • passing gas
  • problems in urinating
  • runny or stuffy nose
  • sexual problems, especially ejaculatory disturbances
  • sleepiness or unusual drowsiness
  • stomach discomfort or upset
  • trouble with sleeping
Less common
  • Abnormal dreams
  • change in sense of taste
  • congestion
  • discouragement, feeling sad, or empty
  • drugged feeling
  • fast or irregular breathing
  • feeling of unreality
  • headache, severe and throbbing
  • increased appetite
  • itching of the vagina or genital area
  • itching, pain, redness, or swelling of the eye or eyelid
  • lack of emotion
  • loss of interest or pleasure
  • lump in the throat
  • menstrual changes
  • pain during sexual intercourse
  • problems with memory
  • sense of detachment from self or body
  • sneezing
  • thick, white vaginal discharge with no odor or with a mild odor
  • tightness in the throat
  • tingling, burning, or prickling sensations
  • trouble concentrating
  • voice changes
  • watering of the eyes
  • weight loss
  • yawn

For Healthcare Professionals

Applies to paroxetine: oral capsule, oral suspension, oral tablet, oral tablet extended release

Gastrointestinal

A study of 26,005 antidepressant users has reported 3.6 times more upper GI bleeding episodes with the use of SSRIs relative to the population who did not receive antidepressant medications. Upper gastrointestinal tract bleeding was observed up to 3.2 times more frequently in patients receiving paroxetine (the active ingredient contained in Pexeva) [Ref]

Gastrointestinal side effects have frequently included nausea (15% to 36%), dry mouth (4% to 36%), constipation (5% to 16%), diarrhea (6% to 19%), increased appetite (3%), decreased appetite (2% to 12%), flatulence (4% to 8%), vomiting (2% to 3%), oropharynx disorder (2%), taste perversion (2%), gingivitis (1%), and dyspepsia (2% to 13%). Bruxism, upper GI bleeding, colitis, dysphagia, eructation, gastritis, gastroenteritis, glossitis, increased salivation, rectal hemorrhage, ulcerative stomatitis, aphthous stomatitis, bloody diarrhea, bulimia, cholelithiasis, duodenitis, enteritis, esophagitis, fecal impaction, fecal incontinence, gum hemorrhage, hematemesis, ileitis, ileus, intestinal obstruction, melena, mouth ulceration, peptic ulcer, peritonitis , salivary gland enlargement, sialadenitis, stomach ulcer, stomatitis, tongue discoloration, tongue edema, loss of taste, and tooth caries have also been reported.[Ref]

Nervous system

Chorea has been reported in 13 patients. One incidence of chorea occurred after a single dose of paroxetine (the active ingredient contained in Pexeva)

Severe psychomotor retardation and stupor have been reported in one patient.

According to the manufacturer, one study reported that seizures occurred in 0.26% of patients treated with other commonly used antidepressants.

In one study, paroxetine was found to decrease rapid eye movement (REM) sleep, increase REM latency, increase awakenings, and reduce actual sleep time. Another study found a decreased amount of REM sleep without a detrimental effect on subjective sleep quality.

Nearly all selective serotonin reuptake inhibitors, mixed serotonin/norepinephrine reuptake inhibitors, and tricyclic antidepressants cause sleep abnormalities to some extent. These antidepressants have marked dose-dependent effects on rapid eye movement (REM) sleep, causing reductions in the overall amount of REM sleep over the night and delays the first entry into REM sleep (increased REM sleep onset latency (ROL)), both in healthy subjects and depressed patients. The antidepressants that increase serotonin function appear to have the greatest effect on REM sleep. The reduction in REM sleep is greatest early in treatment, but gradually returns towards baseline during long-term therapy; however, ROL remains long. Following discontinuation of therapy the amount of REM sleep tends to rebound. Some of these drugs (i.e., bupropion, mirtazapine, nefazodone, trazodone, trimipramine) appear to have a modest or minimal effect on REM sleep.[Ref]

Nervous system side effects have frequently included somnolence (9% to 24%), dizziness (7% to 14%), insomnia (8% to 24%), tremor (4% to 11%), nervousness (2% to 9%), paresthesia (1% to 4%), decreased libido in both male and female patients (3% to 15%), 'drugged' feeling (2%), confusion (1%), sleep abnormalities, abnormal dreams (1% to 4%), impaired concentration (2% to 4%), myoclonus (1% to 3%), amnesia (1% to 2%), tremor (4% to 8%), hypertonia (2% to 3%), and vertigo (2%). Abnormal thinking, alcohol abuse, ataxia, dystonia, dyskinesia, hypesthesia, hypokinesia, incoordination, paralysis, abnormal gait, akinesia, antisocial reaction, aphasia, choreoathetosis, circumoral paresthesias, convulsion, delirium, delusions, dysarthria, extrapyramidal syndrome, fasciculations, grand mal convulsions, hyperalgesia, meningitis, myelitis, neuralgia, neuropathy, nystagmus, peripheral neuritis, decreased reflexes, increased reflexes, stupor, torticollis, trismus, tardive dyskinesia, seizures, status epilepticus, serotonin syndrome, extrapyramidal symptoms (including akathisia, bradykinesia, cogwheel rigidity, dystonia, and hypertonia), changes in rapid eye movement (REM) sleep, chorea, psychomotor retardation, and stupor have also been reported.[Ref]

Psychiatric

Other commonly used antidepressants induced mania in 11% of patients in one study.

Pooled results from clinical trials report hallucinations in 22 of 9089 patients who received paroxetine (the active ingredient contained in Pexeva) and 4 of 3187 patients who received placebo.[Ref]

Psychiatric side effects have frequently included anxiety (2% to 5%), agitation (2% to 5%), depersonalization (3%), depression (2%), lack of emotion (2%), and emotional lability. Euphoria, hallucinations, hostility, increased libido, neurosis, paranoid reaction, antisocial reaction, delusions, drug dependence, hysteria, manic-depressive reaction, psychotic depression, and psychosis. Mania has been reported in up to 2% of bipolar patients.[Ref]

Dermatologic

Seven cases of alopecia have been reported. In all cases, hair loss was eventually reversible.

A case of cutaneous leukocytoclastic vasculitis has been reported following treatment with paroxetine (the active ingredient contained in Pexeva) The patient originally developed the lesions after treatment with escitalopram. The lesions disappeared one week following discontinuation of escitalopram and reappeared upon rechallenge. When the patient was switched to paroxetine a similar reaction occurred.[Ref]

Dermatologic side effects have frequently included sweating (5% to 34%), rash (2% to 3%), photosensitivity (2%), eczema (1%), and pruritus. Acne, alopecia, contact dermatitis, dry skin, ecchymosis, herpes simplex, urticaria, erythema nodosus, erythema multiforme, exfoliative dermatitis, fungal dermatitis, furunculosis, herpes zoster, hirsutism, maculopapular rash, seborrhea, skin discoloration, skin hypertrophy, skin ulcer, decreased sweating, vesiculobullous rash, and toxic epidermal necrolysis have also been reported. Two cases of cutaneous vasculitis have also been reported. Dermatologic side effects reported postmarketing have included Stevens-Johnson syndrome.[Ref]

Genitourinary

Genitourinary side effects reported in males have included ejaculatory disturbance (13% to 28%), impotence (2% to 9%), and priapism. Genitourinary side effects reported in females have included anorgasmia, orgasmic disturbance, dysmenorrhea, eclampsia, menstrual disorder (2%), vaginitis (2%), amenorrhea, menorrhagia, abortion, endometrial disorder, female lactation, leukorrhea, mastitis, salpingitis, uterine spasm, vaginal hemorrhage, metrorrhagia, and vaginal moniliasis. Urinary tract infection (3%), sexual dysfunction, urinary frequency, urinary disorder, difficulty with micturition, urinary hesitancy, breast pain, breast atrophy, breast enlargement, fibrocystic breast, cystitis, dysuria, hematuria, nocturia, polyuria, pyuria, urinary incontinence, urinary retention, urinary urgency, epididymitis, kidney calculus, kidney pain, nephritis, oliguria, urethritis, urinary casts, and urolith have also been reported.[Ref]

There are no controlled clinical data regarding sexual dysfunction with paroxetine use.

There are several reports of priapism associated with paroxetine use. In cases in which outcome was reported, all patients fully recovered.[Ref]

Cardiovascular

Cardiovascular side effects have frequently included palpitation (2% to 3%), vasodilation (2% to 4%), hypertension (2%), and tachycardia (including torsade de pointes). Bradycardia, hematoma, hypotension, postural hypotension, syncope, angioedema, angina pectoris, nodal arrhythmia, atrial fibrillation, bundle branch block, cerebral ischemia, cerebrovascular accident, congestive heart failure, heart block, low cardiac output, myocardial infarct, myocardial ischemia, phlebitis, supraventricular extrasystoles, thrombophlebitis, thrombosis, varicose vein, supraventricular tachycardia, vascular headache, vasculitic syndromes (including Henoch-Schonlein purpura), ventricular extrasystoles, and ventricular fibrillation have also been reported.[Ref]

The effects on blood pressure have been reported to be inconsistent.[Ref]

Endocrine

Paroxetine- induced hyponatremia may be more common in elderly female patients and those who are volume depleted or are receiving concomitant diuretic therapy.[Ref]

Endocrine side effects have included diabetes mellitus, goiter, hyperthyroidism, hypothyroidism, and thyroiditis. Hyperprolactinemia, hyponatremia, and the syndrome of inappropriate antidiuretic hormone (SIADH) are increasingly being associated with selective serotonin reuptake inhibitors including paroxetine. A case of severe life-threatening hyponatremia in a patient receiving paroxetine has been reported.[Ref]

Hematologic

The mechanism of paroxetine- induced bleeding may be related to drug-induced platelet dysfunction.[Ref]

Hematologic side effects have included anemia, leukopenia, lymphadenopathy, purpura, abnormal erythrocytes, basophilia, increased bleeding time, eosinophilia, hypochromic anemia, iron deficiency anemia, leukocytosis, lymphedema, abnormal lymphocytes, lymphocytosis, microcytic anemia, monocytosis, normocytic anemia, thrombocythemia, thrombocytopenia, hemolytic anemia, and events related to impaired hematopoiesis (including aplastic anemia, pancytopenia, bone marrow aplasia, and agranulocytosis). Several cases have also been reported suggesting that paroxetine may cause bleeding in patients with normal bleeding times, platelet counts, prothrombin times, and partial thromboplastin times.[Ref]

Other

Other side effects have frequently included headache (15% to 27%), asthenia (14% to 22%), infection (6% to 8%), abdominal pain (4% to 7%), chest pain (3%), back pain (3% to 5%), chills (2%), migraine (1%), and trauma (3% to 8%). Face edema, withdrawal syndrome, malaise, neck pain, adrenergic syndrome, cellulitis, moniliasis, neck rigidity, pelvic pain, sepsis, ulcer, ear pain, tinnitus, otitis media, deafness, pallor, hyperacusis, otitis externa, parosmia, Guillain-Barre syndrome, and neuroleptic malignant syndrome- like reaction.[Ref]

A withdrawal syndrome, similar to that seen in other selective serotonin reuptake inhibitors, has been reported. Recent clinical trials by the manufacturer reported withdrawal events to be serious in 0.3% of patients who discontinued therapy with controlled-release paroxetine tablets. Patients discontinuing paroxetine have complained of vertigo, lightheadedness, gait instability, malaise, myalgia, middle insomnia, nausea, emesis, diarrhea, and/or visual phenomena (similar to that associated with migraine) during withdrawal. Two cases of behavioral syndromes including severe aggressive and suicidal impulsivity following paroxetine withdrawal have been reported. One case of withdrawal hypomania has been reported. One case of unilateral facial numbness with blurred peripheral vision has also been reported upon withdrawal.

In one retrospective chart review of 352 patients who were supervised during tapering and discontinuation from serotonin reuptake inhibitor therapy, dizziness, lethargy, paresthesia, nausea, vivid dreams, irritability, and lowered mood were the most common symptoms reported. Patients with at least one qualitatively new symptom were defined in the paroxetine group at a rate of 17.2%.

Patients should be monitored for symptoms when discontinuing treatment. A gradual reduction in dosage rather than abrupt discontinuation of therapy is recommended when possible. If intolerable symptoms occur following discontinuation of therapy, then resumption of the previous dose may be considered. Subsequently, discontinuation of therapy may be retried at a more gradual rate.[Ref]

Renal

Renal side effects have included acute renal failure.[Ref]

Respiratory

Respiratory side effects have frequently included respiratory disorder (7%), sinusitis (4% to 8%), yawn (2% to 5%), rhinitis (3% to 4%), increased cough (1% to 2%), bronchitis (1% to 2%), and pharyngitis (4%). Asthma, dyspnea, epistaxis, hyperventilation, pneumonia, respiratory flu, emphysema, hemoptysis, hiccups, lung fibrosis, pulmonary edema, pulmonary embolus, increased sputum, stridor, porphyria, laryngismus, and alteration in voice have also been reported.[Ref]

Hypersensitivity

Hypersensitivity side effects have included allergic reactions in up to 2% of patients including allergic alveolitis and anaphylaxis.[Ref]

Hepatic

Hepatic side effects have included a single case of severe hepatotoxicity with jaundice. Hepatitis and abnormal liver function tests have been reported rarely.[Ref]

The manufacturer states that in placebo-controlled clinical trials patients receiving paroxetine experienced abnormal values on liver function tests at a rate equal to or less than that reported in patients receiving placebo. However, there have been postmarketing reports of patients developing elevated serum transaminases resulting in severe liver dysfunction, as well as, a few cases of elevated liver function tests resulting in death secondary to liver necrosis.[Ref]

Ocular

Ocular side effects have frequently included blurred vision (4%), abnormality of accommodation (2%), and abnormal vision (2% to 5%). Conjunctivitis, eye pain, keratoconjunctivitis, mydriasis, amblyopia, anisocoria, blepharitis, cataract, conjunctival edema, corneal ulcer, diplopia, exophthalmos, eye hemorrhage, glaucoma, night blindness, photophobia, ptosis, retinal hemorrhage, optic neuritis, and visual field effect have also been reported.[Ref]

Musculoskeletal

In one study using the healthcare data from the providence of Ontario, Canada reviewing 8239 patients treated for hip fractures, the adjusted odds ratio for hip fracture was 2.4 for exposure to selective serotonin reuptake inhibitors (including fluoxetine, fluvoxamine, paroxetine (the active ingredient contained in Pexeva) and sertraline), compared to participants who had no exposure to antidepressants.[Ref]

Musculoskeletal side effects have frequently included myopathy (2%), myalgia (2% to 5%), myasthenia (1%), and arthralgia (2%). Arthritis, arthrosis, bursitis, myositis, osteoporosis, generalized spasm, tenosynovitis, and tetany have also been reported. A single case of bruxism has been reported. Postmarketing reports have included restless legs syndrome.[Ref]

Metabolic

Controlled studies reported an average weight loss of approximately 1 pound per patient versus smaller changes reported with placebo.

The results of one study appear to indicate that treatment with selective serotonin reuptake inhibitors (i.e., paroxetine (the active ingredient contained in Pexeva) sertraline, citalopram) may cause an increase in serum total cholesterol, HDL cholesterol, and/or LDL cholesterol. However, additional studies are necessary to confirm these findings.

Numerous cases of hyponatremia have been reported following treatment with a selective serotonin reuptake inhibitor (SSRI). Risk factors for the development of SSRI- associated hyponatremia including advanced age, female gender, concomitant use of diuretics, low body weight, and lower baseline serum sodium levels have been identified. Hyponatremia tends to develop within the first few weeks of treatment (range 3 to 120 days) and typically resolves within 2 weeks (range 48 hours to 6 weeks) after therapy has been discontinued with some patients requiring treatment. The proposed mechanism for the development of hyponatremia involves the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) via release of antidiuretic hormone.[Ref]

Metabolic side effects have frequently included weight gain (3%) and weight loss (1%). Edema, peripheral edema, thirst, bilirubinemia, dehydration, gout, hypercalcemia, hypercholesteremia, hyperglycemia, hyperkalemia, hyperphosphatemia, hypocalcemia, hypoglycemia, hypokalemia, hyponatremia, porphyria, and ketosis have also been reported. In addition, increased levels of SGOT, SGPT, alkaline phosphatase, BUN, creatinine phosphokinase, gamma globulins, lactic dehydrogenase, and non- protein nitrogen (NPN) have been reported. An increase in serum cholesterol has been reported following use of paroxetine.[Ref]

General

General side effects including abnormal bleeding have been reported.[Ref]

References

1. Claghorn JL, Kiev A, Rickels K, Smith WT, Dunbar GC "Paroxetine versus placebo: a double-blind comparison in depressed patients." J Clin Psychiatry 53 (1992): 434-8

2. Ohrberg S, Christiansen PE, Severin B, Calberg H, Nilakantan B, Borup A, Sogaard J, Larsen SB, Loldrup D, Bahr B, et al "Paroxetine and imipramine in the treatment of depressive patients in psychiatric practice." Acta Psychiatr Scand 86 (1992): 437-44

3. Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992): 61-6

4. Feighner JP, Cohn JB, Fabre LF, Jr Fieve RR, Mendels J, Shrivastava RK, Dunbar GC "A study comparing paroxetine placebo and imipramine in depressed patients." J Affect Disord 28 (1993): 71-9

5. Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994): 127-38

6. Dunbar GC, Claghorn JL, Kiev A, Rickels K, Smith WT "A comparison of paroxetine and placebo in depressed outpatients." Acta Psychiatr Scand 87 (1993): 302-5

7. Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-64

8. Patkar AA, Masand PS, Krulewicz S, et al. "A randomized, controlled, trial of controlled release paroxetine in fibromyalgia." Am J Med 120 (2007): 448-54

9. Kirsch MA, Louie AK "Paroxetine and irritable bowel syndrome." Am J Psychiat 157 (2000): 1523-4

10. Wilson S, Argyropoulos S "Antidepressants and sleep: a qualitative review of the literature." Drugs 65 (2005): 927-47

11. Staner L, Kerkhofs M, Detroux D, Leyman S, Linkowski P, Mendlewicz J "Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression." Sleep 18 (1995): 470-7

12. Adler LA, Angrist BM "Paroxetine and akathisia." Biol Psychiatry 37 (1995): 336-7

13. Olivera AA "A case of paroxetine-induced akathisia." Biol Psychiatry 39 (1996): 910

14. Pacheco L, Malo P, Aragues E, Etxebeste M "More cases of paroxetine withdrawal syndrome." Br J Psychiatry 169 (1996): 384

15. Botsaris SD, Sypek JM "Paroxetine and tardive dyskinesia." J Clin Psychopharmacol 16 (1996): 258-9

16. Jimenez-Jimenez FJ, Tejeiro J, Martinez-Junquero G, Cabrera-Valdivia F, Alarcon J, Garcia-Albea E "Parkinsonism exacerbated by paroxetine." Neurology 44 (1994): 2406

17. Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-552

18. Fox GC, Ebeid S, Vincenti G "Paroxetine-induced chorea." Br J Psychiatry 170 (1997): 193-4

19. Fava GA, Grandi S "Withdrawal syndromes after paroxetine and sertraline discontinuation." J Clin Psychopharmacol 15 (1995): 374-5

20. Bloch M, Stager SV, Braun AR, Rubinow DR "Severe psychiatric symptoms associated with paroxetine withdrawal." Lancet 346 (1995): 57

21. Phillips SD "Possible paroxetine withdrawal syndrome." Am J Psychiatry 152 (1995): 645-6

22. Lewis J, Braganza J, Williams T "Psychomotor retardation and semistuporous state with paroxetine." BMJ 306 (1993): 1169

23. Sharpley AL, Williamson DJ, Attenburrow MEJ, Pearson G, Sargent P, Cowen PJ "The effects of paroxetine and nefazodone on sleep: a placebo controlled trial." Psychopharmacology (Berl) 126 (1996): 50-4

24. "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.

25. Morishita S, Arita S "Prevalence of induced mania in patients treated with milnacipran: a comparison with paroxetine." Eur Psychiatry 19 (2004): 315-6

26. Marcy TR, Britton ML "Antidepressant-induced sweating." Ann Pharmacother 39 (2005): 748-52

27. Flores-Suarez LF, Vega-Memije ME, Chanussot-Deprez C "Cutaneous vasculitis during selective serotonin reuptake inhibitor therapy." Am J Med 119 (2006): e1-3

28. Ahmed R, Eagleton C "Toxic epidermal necrolysis after paroxetine treatment." N Z Med J 121 (2008): 86-9

29. Margolese HC, Chouinard G, Beauclair L, Rubino M "Cutaneous vasculitis induced by paroxetine." Am J Psychiat 158 (2001): 497

30. Gautam M "Alopecia due to psychotropic medications." Ann Pharmacother 33 (1999): 631-7

31. Rothschild AJ "Sexual side effects of antidepressants." J Clin Psychiatry 61 (2000): 28-36

32. Ahmad S "Paroxetine-induced priapism." Arch Intern Med 155 (1995): 645

33. Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982): 351-7

34. Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995): 390

35. Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993): 143

36. Madhusoodanan S, Brenner R, Brafman I, Bogunovic O "Hyponatremia associated with paroxetine use." South Med J 92 (1999): 843

37. Odeh M, Seligmann H, Oliven A "Severe life-threatening hyponatremia during paroxetine therapy." J Clin Pharmacol 39 (1999): 1290-1

38. Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992): 1332

39. van Campen JP, Voets AJ "SIADH caused by paroxetine." Ann Pharmacother 30 (1996): 1499

40. Spigset O, hedenmalm K "Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions." Pharmacotherapy 17 (1997): 348-52

41. Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2

42. Coupland NJ, Bell CJ, Potokar JP "Serotonin reuptake inhibitor withdrawal." J Clin Psychopharmacol 16 (1996): 356-62

43. Landry P, Roy L "Withdrawal hypomania associated with paroxetine." J Clin Psychopharmacol 17 (1997): 60-1

44. Strickland GM, Hough DW "Unilateral facial numbness and visual blurring associated with paroxetine discontinuation." J Clin Psychopharmacol 20 (2000): 271-2

45. Dahl ML, Olhager E, Ahlner J "Paroxetine withdrawal syndrome in a neonate." Br J Psychiatry 171 (1997): 391-2

46. Odeh M, Misselevech I, Boss JH, Oliven A "Severe hepatotoxicity with jaundice associated with paroxetine." Am J Gastroenterol 96 (2001): 2494-6

47. Romanelli F, Adler DA, Bungay KM "Possible paroxetine-induced bruxism." Ann Pharmacother 30 (1996): 1246-8

48. Liu B, Anderson G, Mittmann N, To Teresa, Axcell T, Shear N "Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people." Lancet 351 (1998): 1303-7

49. Jacob S, Spinler SA "Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults." Ann Pharmacother 40 (2006): 1618-22

50. Herran A, Ramirez ML, Carrera M, et al. "Panic disorder, treatment with selective serotonin reuptake inhibitors, and cholesterol levels." J Clin Psychopharmacol 26 (2006): 538-40

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web3)